Sources: Elon Musk approached brain-computer interface developer Synchron about a potential investment, after expressing frustration with Neuralink's progress
Rachael Levy / Reuters :
Context & Ripple Effects
Five years after [[a:917643|launching Neuralink to implant electrodes that read and write thoughts directly to the cortex]], Elon Musk is reportedly shopping for a second bet in the same field — approaching endovascular BCI developer Synchron about an investment while expressing frustration with his own startup's pace. The corpus shows why the impatience landed: Neuralink set a goal of testing on humans by Q2 2020 back when it had raised $158M including $100M of Musk's own money.
The approach matters because it signals a founder-patron hedging between rival technical routes rather than doubling down — a year later Neuralink would still command the field's biggest check, a $280M Series D led by Founders Fund at a reported ~$5B valuation, but this moment marks the first crack in the assumption that Musk's capital flows only one way.
First-order effects
- Synchron suddenly has leverage: interest from the sector's richest individual investor raises its fundraising options and negotiating position without a term sheet even being signed.
- Neuralink's leadership now answers to a founder publicly signaling dissatisfaction, raising pressure to show clinical progress or risk capital and attention shifting to a competitor.
Second-order effects
- A Musk investment in Synchron would validate the endovascular approach against Neuralink's implanted-electrode route, forcing other BCI startups and their backers to defend which method reaches human trials first.
- Rival investors get a pricing signal: if Musk is willing to pay for a second BCI platform, valuations across the small pool of credible neurotech companies rise.
Third-order effects
- If the pattern holds, brain-computer interfaces consolidate around whichever approach can hold onto patient billionaire capital through long regulatory timelines — making founder tolerance for slow progress, not just science, the industry's scarce resource.
- The episode previews a structure where single patrons hedge across competing labs in frontier fields, concentrating exit paths and strategic direction in a handful of individuals rather than distributed venture syndicates.
The trend: Frontier neurotech is entering a phase where billionaire patrons hedge across rival technical approaches, and founder frustration — not just funding rounds — redirects capital between competing platforms.